One-shot treatment Kymriah passed the cancer committee

HIRA unveiled the expansion of benefit standards for the first time

AbbVie's Venxta's benefit standard setting

Kymriah (Tisagenlecleucel) of Novartis Korea, a "one-shot treatment" with an ultra-high cost of 500 million won per dose, passed the Cancer Drugs Benefit Appraisal Committee.

 

At the Cancer Drugs Benefit Appraisal Committee held last month, the gap between health authorities and pharmaceutical companies was barely narrowed at the second Cancer Drugs Benefit Appraisal Committee.

 

The HIRA released the "7th Cancer Drugs Benefit Appraisal Committee Deliberation Results in 2021" on the afternoon of the 13th.

 

The HIRA, like the Cancer Drugs Benefit Appraisal Committee and the Cancer Drugs Benefit Appraisal Committee this month, decided to disclose the results of the deliberation to the media after the meeting.

 

According to the results of today's meeting, Kymriah's benefit criteria were set for both indications: adult diffuse giant B-cell lymphoma and B-cell acute lymphocytic leukemia (ALL) in children and young adults.

 

After 60 days of drug price negotiations with the NHIS after being recognized by the Drug Reimbursement Evaluation Committee, it must pass the Health Insurance Policy Committee to be listed on the list in earnest.

 

Kymriah used Drug Approval-Linkage Systems in March to register benefits with approval from the MFDS.

 

At the Cancer Drugs Benefit Appraisal Committee with Kymriah, there was a discussion on the expansion of benefit standards, but all of them failed to pass the Cancer Drugs Benefit Appraisal Committee except for the Benetoclax combination therapy of AbbVie Korea.

 

Drugs that have not been set based include FOLFOX (Folinic acid, Fluorouracil, and Oxaliplatin), chronic lymphocytic leukemia treatment Imbruvica(Ibrutinib) by Janssen Korea, and B-cell acute lymphocyte leukemia treatment Blincyto (Blinatumomab).